

- Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. *CA Cancer J Clin* 2014; 64:9–29.
- Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. *J Natl Cancer Inst* 2010;102:1114–1130.
- Bray F, Ferlay J, Devesa SS, et al. Interpreting the international trends in testicular seminoma and nonseminoma incidence. *Nat Clin Pract Urol* 2006;3: 532–543.
- Rapley EA, Nathanson KL. Predisposition alleles for testicular germ cell tumor. *Curr Opin Genet Dev* 2010;20:225–230.
- Dieckmann KP, Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. *World J Urol* 2004;22:2–14.
- Husmann DA. Cryptorchidism and its relationship to testicular neoplasia and microlithiasis. *Urology* 2005;66:424–426.
- Schaapveld M, van dan Belt-Dusebout AW, Gietema JA, et al. Risk and prognostic significance of metachronous contralateral testicular germ cell tumours. *Br J Cancer* 2012;107:1637–1643.
- Looijenga LH, Van Aghoven T, Biermann K. Development of malignant germ cells—the germline hypothesis. *Int J Dev Biol* 2013;57:241–253.
- McGlynn KA, Devesa SS, Sugarman AJ, et al. Trends in the incidence of testicular germ cell tumors in the United States. *Cancer* 2003;97:63–70.
- Hussain SA, Ma YT, Palmer DH, et al. Biology of testicular germ cell tumors. *Expert Rev Anticancer Ther* 2008;8:1659–1673.
- Sheikine Y, Genega E, Melamed J, et al. Molecular genetics of testicular germ cell tumors. *Am J Cancer Res* 2012;2:153–167.
- Tan MH, Eng C. Testicular microlithiasis: recent advances in understanding and management. *Nat Rev Urol* 2011;8:153–163.
- Peterson AC, Bauman JM, Light DE, et al. The prevalence of testicular microlithiasis in an asymptomatic population of men 18 to 35 years old. *J Urol* 2001;166:2061–2064.
- Coffey J, Huddart RA, Elliott F, et al. Testicular microlithiasis as a familial risk factor for testicular germ cell tumour. *Br J Cancer* 2007;97:1701–1706.
- Rao B, Pagliaro LC. Testicular germ cell tumors. In: Silverman PM, ed. *Oncologic Imaging: A Multidisciplinary Approach*. Philadelphia: Elsevier; 2012:335–357.
- Bosl GJ, Vogelzang NJ, Goldman A, et al. Impact of delay in diagnosis on clinical stage of testicular cancer. *Lancet* 1981;2:970–973.
- Barlow LJ, Badalato GM, McKiernan JM. Serum tumor markers in the evaluation of male germ cell tumors. *Nat Rev Urol* 2010;7:610–617.
- Richie JP. Surgical aspects in the treatment of patients with testicular cancer. *Hematol Oncol Clin North Am* 1991;5:1127–1142.
- Chieffi P, Franco R, Portella G. Molecular and cell biology of testicular germ cell tumors. *Int Rev Cell Mol Biol* 2009;278:277–308.
- Eble JN, Sauter G, Epstein JI, et al., eds. *Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*. Lyon, France: IARC Press; 2004.
- Lempiäinen A, Sankila A, Hotakainen K, et al. Expression of human chorionic gonadotropin in testicular germ cell tumors. *Urol Oncol* 2014 (pub ahead of print).
- Nazeer T, Ro JY, Amato RJ, et al. Histologically pure seminoma with elevated alpha-fetoprotein: a clinicopathologic study of ten cases. *Oncol Rep* 1998;5:1425–1429.
- Chieffi P, Chieffi S, Franco R, et al. Recent advances in the biology of germ cell tumors: implications for the diagnosis and treatment. *J Endocrinol Invest* 2012;35:1015–1020.
- Gigantino V, La Mantia E, Franco R, et al. Testicular and testicular adnexa tumors in the elderly. *Anticancer Drugs* 2013;24:228–236.
- Almstrup K, Hoei-Hansen CE, Wirkner U, et al. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. *Cancer Res* 2004;64:4736–4743.
- Houldsworth J, Korkola JE, Bosl GJ, et al. Biology and genetics of adult male germ cell tumors. *J Clin Oncol* 2006;24:5512–5518.
- Alvarado-Cabrero I, Hernandez-Toriz N, Paner GP. Clinicopathologic analysis of choriocarcinoma as a pure or predominant component of germ cell tumor of the testis. *Am J Surg Pathol* 2014;38:111–118.
- Ehrlich Y, Beck SD, Ulbright TM, et al. Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. *Ann Oncol* 2010; 21:1846–1850.
- Rabbani F, Farivar-Mohseni H, Leon A, et al. Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. *Urology* 2003;62:1092–1096.
- Donadio AC, Motzer RJ, Bajorin DF, et al. Chemotherapy for teratoma with malignant transformation. *J Clin Oncol* 2003;21:4285–4291.
- Ma YT, Cullen MH, Hussain SA. Biology of germ cell tumors. *Hematol Oncol Clin North Am* 2011;25:457–471, vii.
- Geurts van Kessel A, van Druenen E, de Jong B, et al. Chromosome 12q heterozygosity is retained in i(12p)-positive testicular germ cell tumor cells. *Cancer Genet Cytogenet* 1989;40:129–134.
- Gilbert D, Rapley E, Shipley J. Testicular germ cell tumours: predisposition genes and the male germ cell niche. *Nat Rev Cancer* 2011;11:278–288.
- Greene MH, Kratz CP, Mai PL, et al. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. *Endocr Relat Cancer* 2010;17:R109–R121.
- Smiraglia DJ, Szymanska J, Kragerud SM, et al. Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. *Oncogene* 2002;21:3909–3916.
- Netto GJ, Nakai Y, Makayama M, et al. Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors. *Mod Pathol* 2008;21:1337–1344.
- Emerson RE, Ulbright TM. Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers. *Pathology* 2010;42:344–355.
- Cao D, Li J, Guo CC, et al. SALL4 is a novel diagnostic marker for testicular germ cell tumors. *Am J Surg Pathol* 2009;33:1065–1077.
- Wang F, Liu A, Peng Y, et al. Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immunohistochemical study of 59 cases with comparison to placental-like alkaline phosphatase, alpha-fetoprotein, and glypican-3. *Am J Surg Pathol* 2009;33:1529–1539.
- American Joint Committee on Cancer. Testis. In: Edge SB, Byrd DR, Compton CC, eds. *AJCC Cancer Staging Manual*. 7th ed. New York: Springer-Verlag; 2010:471–472.
- Dixon AK, Ellis M, Sikora K. Computed tomography of testicular tumours: distribution of abdominal lymphadenopathy. *Clin Radiol* 1986;37:519–523.
- Tickoo SK, Hutchinson B, Bacik J, et al. Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical features. *Int J Surg Pathol* 2002;10:23–32.
- Gholam D, Fizazi K, Terrier-Lacombe MJ, et al. Advanced seminoma—treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients. *Cancer* 2003;98:745–752.
- International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. *J Clin Oncol* 1997;15:594–603.
- Vugrin D, Chen A, Feigl P, et al. Embryonal carcinoma of the testis. *Cancer* 1988;61:2348–2352.
- Germa JR, Arcusa A, Casamitjana R. False elevations of human chorionic gonadotropin associated to iatrogenic hypogonadism in gonadal germ cell tumors. *Cancer* 1987;60:2489–2493.
- Morris MJ, Bosl GJ. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. *J Urol* 2000;163:796–801.
- Pagliaro LC. Testicular cancer: when less is more. *Curr Oncol Rep* 2010; 12:271–277.
- Beard CJ, Travis LB, Chen MH, et al. Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. *Cancer* 2013;119:2771–2777.
- Chung P, Parker C, Panzarella T, et al. Surveillance in stage I testicular seminoma—risk of late relapse. *Can J Urol* 2002;9:1637–1640.
- Roper MS, Hastings JR, Cosmatos HA, et al. Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma: clinical outcomes and prognostic factors for relapse in a large US cohort. *Am J Clin Oncol* 2012.
- Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. *Lancet* 2005;366:293–300.
- Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). *J Clin Oncol* 2011;29:957–962.
- National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology*. Fort Washington, PA: National Comprehensive Cancer Network; 2014.
- Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). *J Clin Oncol* 2005;23:1200–1208.
- Sharda NN, Kinsella TJ, Ritter MA. Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. *J Clin Oncol* 1996;14:2933–2939.
- Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. *J Natl Cancer Inst* 1997;89:1429–1439.
- Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. *J Natl Cancer Inst* 2005;97:1354–1365.
- Nallu A, Mannuel HD, Hussain A. Testicular germ cell tumors: biology and clinical update. *Curr Opin Oncol* 2013;25:266–272.
- Sturgeon JF, Moore MJ, Kakiashvili DM, et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. *Eur Urol* 2011;59:556–562.
- Afshar K, Lodha A, Costei A, et al. Recruitment in pediatric clinical trials: an ethical perspective. *J Urol* 2005;174:835–840.
- Stephenson AJ, Bosl GJ, Bajorin DF, et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. *J Urol* 2005;174:557–560; discussion 560.

63. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. *N Engl J Med* 1987;316:1435–1440.
64. Behnia M, Foster R, Einhorn LH, et al. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. The Indiana University experience. *Eur J Cancer* 2000;36:472–475.
65. Swanson DA. Two courses of chemotherapy after orchidectomy for high-risk clinical stage I nonseminomatous testicular tumours. *BJU Int* 2005;95:477–478.
66. Albers P, Siener R, Krege S, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. *J Clin Oncol* 2008;26:2966–2972.
67. Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. *J Clin Oncol* 2009;27:2122–2128.
68. Dearnaley DP, Fossa SD, Kaye SB, et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). *Br J Cancer* 2005;92:2107–2113.
69. Stephenson AJ, Bosl CJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. *J Clin Oncol* 2005;23:2781–2788.
70. Eggener SE, Carver BS, Sharp DS, et al. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. *J Urol* 2007;177:937–942; discussion 942–943.
71. Donohue JP, Thornhill JA, Foster RS, et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. *J Urol* 1993;149:237–243.
72. Sheinfeld J. Mapping studies and modified templates in nonseminomatous germ cell tumors. *Nat Clin Pract Urol* 2007;4:60–61.
73. Carver BS, Shayegan B, Eggener S, et al. Incidence of metastatic non-seminomatous germ cell tumor outside the boundaries of a modified post-chemotherapy retroperitoneal lymph node dissection. *J Clin Oncol* 2007;25:4365–4369.
74. Davol P, Sumfest J, Rukstalis D. Robotic-assisted laparoscopic retroperitoneal lymph node dissection. *Urology* 2006;67:199.
75. Williams SB, Lau CS, Josephson DY. Initial series of robot-assisted laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer. *Eur Urol* 2011;60:1299–1302.
76. Steiner H, Peschel R, Janetschek G, et al. Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. *Urology* 2004;63:550–555.
77. Classen J, Schmidberger H, Meisner C, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. *J Clin Oncol* 2003;21:1101–1106.
78. Chung PW, Warde PR, Panzarella T, et al. Appropriate radiation volume for stage IIA/B testicular seminoma. *Int J Radiat Oncol Biol Phys* 2003;56:746–748.
79. Neill M, Warde P, Fleshner N. Management of low-stage testicular seminoma. *Urol Clin North Am* 2007;34:127–136; abstract vii–viii.
80. Chung PW, Gospodarowicz MK, Panzarella T, et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. *Eur Urol* 2004;45:754–759; discussion 759–760.
81. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. *J Clin Oncol* 2007;25:4370–4378.
82. Fizazi K, Delva R, Caty A, et al. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study. *Eur Urol* 2014;65:381–386.
83. Rabbani F, Sheinfeld J, Farivar-Mohseni H, et al. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. *J Clin Oncol* 2001;19:2020–2025.
84. Stephenson AJ, Bosl CJ, Motzer RJ, et al. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. *J Clin Oncol* 2007;25:5597–5602.
85. Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. *J Natl Cancer Inst* 1999;91:839–846.
86. Thibault C, Fizazi K, Barrios D, et al. Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours. *Eur J Cancer* 2014;50:1284–1290.
87. Moran CA, Suster S, Przygodzki RM, et al. Primary germ cell tumors of the mediastinum: II. Mediastinal seminomas—a clinicopathologic and immunohistochemical study of 120 cases. *Cancer* 1997;80:691–698.
88. Oldenburg J, Alfsen GC, Lien HH, et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. *J Clin Oncol* 2003;21:3310–3317.
89. Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. *J Clin Oncol* 2005;23:9290–9294.
90. Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). *Ann Oncol* 2007;18:917–924.
91. Bajorin DF, Sarosdy MF, Pfister DC, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. *J Clin Oncol* 1993;11:598–606.
92. Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. *Cancer* 2003;97:1869–1875.
93. Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. *J Clin Oncol* 1998;16:692–701.
94. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. *J Clin Oncol* 2007;25:247–256.
95. Beck SD, Patel MI, Sheinfeld J. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. *J Urol* 2004;171:168–171.
96. Fizazi K, Culine S, Kramar A, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. *J Clin Oncol* 2004;22:3868–3876.
97. Fizazi K, Pagliaro LC, Flechon A, et al. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13 (meeting abstract). *J Clin Oncol* 2013;31.
98. Forquer JA, Harkenrider M, Fakiris AJ, et al. Brain metastasis from non-seminomatous germ cell tumor of the testis. *Expert Rev Anticancer Ther* 2007;7:1567–1580.
99. Goodarzi MO, Van Herle AJ. Thyrotoxicosis in a male patient associated with excess human chorionic gonadotropin production by germ cell tumor. *Thyroid* 2000;10:611–619.
100. Giral SA, Dexeus F, Amato R, et al. Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. *Cancer* 1992;69:1286–1290.
101. Moran CA, Suster A. Primary germ cell tumors of the mediastinum: I. Analysis of 322 cases with special emphasis on teratomatous lesions and a proposal for histopathologic classification and clinical staging. *Cancer* 1997;80:681–690.
102. McNeil MM, Leong AS, Sage RE. Primary mediastinal embryonal carcinoma in association with Klinefelter’s syndrome. *Cancer* 1981;47:343–345.
103. Nichols CR, Heerema NA, Palmer C, et al. Klinefelter’s syndrome associated with mediastinal germ cell neoplasms. *J Clin Oncol* 1987;5:1290–1294.
104. Logothetis CJ, Samuels ML, Selig DE, et al. Chemotherapy of extragonadal germ cell tumors. *J Clin Oncol* 1985;3:316–325.
105. Rodney AJ, Tannir NM, Siefer-Radtke AO, et al. Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience. *Urol Oncol* 2012;30:879–885.
106. Nichols CR, Saxman S, Williams SD, et al. Primary mediastinal nonseminomatous germ cell tumors. A modern single institution experience. *Cancer* 1990;65:1641–1646.
107. Fizazi K, Culine S, Droz JP, et al. Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. *J Clin Oncol* 1998;16:725–732.
108. Bokemeyer C, Nichols CR, Droz JP, et al. Extragenital germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. *J Clin Oncol* 2002;20:1864–1873.
109. Radaideh SM, Cook VC, Kesler KA, et al. Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy. *Ann Oncol* 2010;21:804–807.
110. Moran CA, Suster S, Koss MN. Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum—a clinicopathologic and immunohistochemical study of 64 cases. *Cancer* 1997;80:699–707.
111. Baniel J, Foster RS, Rowland RC, et al. Complications of primary retroperitoneal lymph node dissection. *J Urol* 1994;152:424–427.
112. Loehrer PJ Sr, Einhorn LH, Williams SD. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. *J Clin Oncol* 1986;4:528–536.
113. Motzer RJ, Cooper K, Geller NL, et al. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. *Cancer* 1990;66:2476–2481.
114. Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. *J Clin Oncol* 1998;16:2500–2504.

115. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. *J Clin Oncol* 2005;23:6549–6555.
116. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. *N Engl J Med* 2007;357:340–348.
117. Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. *J Clin Oncol* 2010;28:1706–1713.
118. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. *J Clin Oncol* 2004;22:108–114.
119. Einhorn LH, Brames MJ, Juliar B, et al. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. *J Clin Oncol* 2007;25:513–516.
120. Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. *Ann Oncol* 2008;19:448–453.
121. Cooper MA, Einhorn LH. Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. *J Clin Oncol* 1995;13:1167–1169.
122. Oechsle K, Honecker F, Cheng T, et al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. *Ann Oncol* 2011;22:2654–2660.
123. Feldman DR, Turkula S, Ginsberg MS, et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. *Invest New Drugs* 2010;28:523–528.
124. Vaughn DJ, Flaherty K, Lal P, et al. Treatment of growing teratoma syndrome. *N Engl J Med* 2009;360:423–424.
125. Eggener SE, Carver BS, Loeb S, et al. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. *Cancer* 2007;109:528–535.
126. Murphy BR, Breedon ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. *J Clin Oncol* 1993;11:324–329.
127. Eastham JA, Wilson TG, Russell C, et al. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. *Urology* 1994;43:74–80.
128. Carver BS, Motzer RJ, Kondagunta GV, et al. Late relapse of testicular germ cell tumors. *Urol Oncol* 2005;23:441–445.
129. Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. *J Clin Oncol* 2005;23:6999–7004.
130. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. *J Clin Oncol* 2000;18:1725–1732.
131. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. *J Clin Oncol* 2003;21:1513–1523.
132. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. *JAMA* 2013;309:1359–1367.
133. Argyriou AA, Bruna J, Marmioli P, et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. *Crit Rev Oncol Hematol* 2012;82:51–77.
134. Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. *Lancet* 2000;355:1075–1076.
135. Travis LB, Fossa SD, Sesso HD, et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. *J Natl Cancer Inst* 2014;106.
136. Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. *J Clin Oncol* 2006;24:918–924.
137. Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. *J Clin Oncol* 2007;25:708–714.
138. Kaasa S, Aass N, Mastekaasa A, et al. Psychosocial well-being in testicular cancer patients. *Eur J Cancer* 1991;27:1091–1095.
139. Gritz ER, Wellisch DK, Wang HJ, et al. Long-term effects of testicular cancer on sexual functioning in married couples. *Cancer* 1989;64:1560–1567.
140. Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. *J Clin Oncol* 1998;16:3386–3391.
141. Nichols CR, Hoffman R, Einhorn LH, et al. Hematologic malignancies associated with primary mediastinal germ-cell tumors. *Ann Intern Med* 1985;102:603–609.
142. Chaganti RS, Ladanyi M, Samaniego F, et al. Leukemic differentiation of a mediastinal germ cell tumor. *Genes Chromosomes Cancer* 1989;1:83–87.
143. Ladanyi M, Samaniego D, Reuter VE, et al. Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. *J Natl Cancer Inst* 1990;82:221–227.
144. Orazi A, Neiman RS, Ulbright TM, et al. Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors. *Cancer* 1993;71:3873–3881.
145. Di Tonno F, Tavolini IM, Belmonte P, et al. Lessons from 52 patients with leydig cell tumor of the testis: the GUONE (North-Eastern Uro-Oncological Group, Italy) experience. *Urol Int* 2009;82:152–157.
146. Giglio M, Medica M, De Rose AF, et al. Testicular sertoli cell tumours and relative sub-types. Analysis of clinical and prognostic features. *Urol Int* 2003;70:205–210.
147. Miliaras D, Anagnostou E, Moysides I. Adult type granulosa cell tumor: a very rare case of sex-cord tumor of the testis with review of the literature. *Case Rep Pathol* 2013;932086.
148. Plas E, Riedl CR, Pfluger H. Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters. *Cancer* 1998;83:2437–2446.
149. Perimenis P, Athanasopoulos A, Speakman M. Primary adenocarcinoma of the rete testis. *Int Urol Nephrol* 2003;35:373–374.
150. Smith AK, Hansel DE, Klein EA. Epidermoid cyst of the testicle. *Urology* 2009;74:544.